HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 767-770

  Kikuchi, Kiyoshi ^a   Uchikado, Hisaaki ^b   Miura, Naoki ^e   Morimoto, Yoko ^c   Ito, Takashi ^c   Tancharoen, Salunya ^d   Miyata, Kei ^c   Sakamoto, Rokudai ^a   Kikuchi, Chiemi ^f   Iida, Narumi ^g   Shiomi, Naoto ^h   Kuramoto, Terukazu ⁱ   Miyagi, Naohisa ^a   Kawahara, Ko Ichi ^c,j  

^a Yame General Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d MAHIDOL UNIVERSITY   (Thailand)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f Nishida Koutoku Hospital   (Japan)

^g Research Laboratory   (Japan)

^h Medical Care Center   (Japan)

ⁱ Omuta City General Hospital   (Japan)

^j OSAKA INSTITUTE OF TECHNOLOGY   (Japan)

more..

Author keywords

High mobility group box 1; Spinal cord injury; Transplantation

Indexed keywords

CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; MONOCLONAL ANTIBODY; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

CELL TRANSPLANTATION; DISEASE SEVERITY; GRAFT REJECTION; HUMAN; HYPOTHESIS; NONHUMAN; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; RNA INTERFERENCE; SPINAL CORD INJURY; SPINAL CORD REGENERATION;

EID: 79960267925     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.310     Document Type: Review

References (61)

1. McDonald JW and Sadowsky C: Spinal-cord injury. Lancet 359: 417-425, 2002.
2. Andersson U, Wang H, Palmblad K, et al: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570, 2000.
3. Ao Q, Wang AJ, Chen GQ, Wang SJ, Zuo HC and Zhang XF: Combined transplantation of neural stem cells and olfactory ensheathing cells for the repair of spinal cord injuries. Med Hypotheses 69: 1234-1237, 2007.
4. Rosenfeld JV, Bandopadhayay P, Goldschlager T and Brown DJ: The ethics of the treatment of spinal cord injury: stem cell transplants, motor neuroprosthetics, and social equity. Top Spinal Cord Inj Rehabil 14: 76-88, 2008.
5. Gupta R, Bathen ME, Smith JS, Levi AD, Bhatia NN and Steward O: Advances in the management of spinal cord injury. J Am Acad Orthop Surg 18: 210-222, 2010.
6. Choi D, Law S, Raisman G and Li D: Olfactory ensheathing cells in the nasal mucosa of the rat and human. Br J Neurosurg 22: 301-302, 2008.
7. Couzin J: Biotechnology. Celebration and concern over U.S. trial of embryonic stem cells. Science 323: 568, 2009.
8. Iwatsuki K, Yoshimine T, Kishima H, et al: Transplantation of olfactory mucosa following spinal cord injury promotes recovery in rats. Neuroreport 19: 1249-1252, 2008.
9. Li Y, Yamamoto M, Raisman G, Choi D and Carlstedt T: An experimental model of ventral root repair showing the beneficial effect of transplanting olfactory ensheathing cells. Neurosurgery 60: 734-741, 2007.
10. Lima C, Pratas-Vital J, Escada P, Hasse-Ferreira A, Capucho C and Peduzzi JD: Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med 29: 191-206, 2006.
11. Okano H: Strategies toward CNS-regeneration using induced pluripotent stem cells. Genome Inform 23: 217-220, 2009.
12. Raisman G: Repair of spinal cord injury by transplantation of olfactory ensheathing cells. C R Biol 330: 557-560, 2007.
13. Raisman G and Li Y: Repair of neural pathways by olfactory ensheathing cells. Nat Rev Neurosci 8: 312-319, 2007.
14. Tsuji O, Miura K, Okada Y, et al: Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Natl Acad Sci USA 107: 12704-12709, 2010.
15. Zurita M and Vaquero J: Functional recovery in chronic paraplegia after bone marrow stromal cell transplantation. Neuroreport 15: 1105-1108, 2004.
16. Agresti A and Bianchi ME: HMGB proteins and gene expression. Curr Opin Genet Dev 13: 170-178, 2003.
17. Dumitriu IE, Baruah P, Valentinis B, et al: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174: 7506-7515, 2005.
18. Inoue K, Kawahara K, Biswas KK, et al: HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 16: 136-143, 2007.
19. Ito T, Kawahara K, Nakamura T, et al: High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 5: 109-116, 2007.
20. Morimoto Y, Kawahara KI, Tancharoen S, et al: Tumor necrosis factor-alpha stimulates gingival epithelial cells to release high mobility-group box 1. J Period Res 43: 76-83, 2008.
21. Rovere-Querini P, Capobianco A, Scaffidi P, et al: HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5: 825-830, 2004.
22. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
23. Taniguchi N, Kawahara K, Yone K, et al: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48: 971-981, 2003.
24. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M and Oppenheim JJ: High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukocyte Biol 81: 59-66, 2007.
25. Park JS, Gamboni-Robertson F, He Q, et al: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol 290: C917-C924, 2006.
26. Park JS, Svetkauskaite D, He Q, et al: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377, 2004.
27. Hori O, Brett J, Slattery T, et al: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761, 1995.
28. Kokkola R, Andersson A, Mullins G, et al: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61: 1-9, 2005.
29. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
30. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME and Rovere-Querini P: HMGB1: guiding immunity from within. Trends Immunol 26: 381-387, 2005.
31. Goldstein RS, Gallowitsch-Puerta M, Yang L, et al: Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25: 571-574, 2006.
32. Kikuchi K, Kawahara K, Biswas KK, et al: Minocycline attenuates both OGD-induced HMGB1 release and HMGB1-induced cell death in ischemic neuronal injury in PC12 cells. Biochem Biophys Res Commun 385: 132-136, 2009.
33. Kikuchi K, Kawahara K, Tancharoen S, et al: The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exper Ther 329: 865-874, 2009.
34. Kim JB, Sig Choi J, Yu YM, et al: HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26: 6413-6421, 2006.
35. Lindstrom O, Tukiainen E, Kylanpaa L, et al: Circulating levels of a soluble form of receptor for advanced glycation end products and high-mobility group box chromosomal protein 1 in patients with acute pancreatitis. Pancreas 38: e215-e220, 2009.
36. Liu K, Mori S, Takahashi HK, et al: Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21: 3904-3916, 2007.
37. Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev 5: 331-342, 2005.
38. Nakahara T, Tsuruta R, Kaneko T, et al: High-mobility group box 1 protein in CSF of patients with subarachnoid hemorrhage. Neurocrit Care 11: 362-368, 2009.
39. Qiu J, Nishimura M, Wang Y, et al: Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 28: 927-938, 2008.
40. Takano K, Shinoda M, Tanabe M, et al: Protective effect of high-mobility group box 1 blockade on acute liver failure in rats: (HMGB1 blockade for rat acute liver failure). Shock 34: 573-579, 2010.
41. Ulloa L and Messmer D: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17: 189-201, 2006.
42. Van Zoelen MA, Ishizaka A, Wolthuls EK, Choi G, van der Poll T and Schultz MJ: Pulmonary levels of high-mobility group box 1 during mechanical ventilation and ventilator-associated pneumonia. Shock 29: 441-445, 2008.
43. Kohno T, Anzai T, Naito K, et al: Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 81: 565-573, 2009.
44. Maeda S, Hikiba Y, Shibata W, et al: Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 360: 394-400, 2007.
45. Sawa H, Ueda T, Takeyama Y, et al: Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World J Gastroenterol 12: 7666-7670, 2006.
46. Ulloa L, Batliwalla FM, Andersson U, Gregersen PK and Tracey KJ: High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum 48: 876-881, 2003.
47. Watanabe T, Kubota S, Nagaya M, et al: The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J Surg Res 124: 59-66, 2005.
48. Yang R, Harada T, Mollen KP, et al: Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 12: 105-114, 2006.
49. Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukocyte Biol 81: 1-5, 2007.
50. Oppenheim JJ and Yang D: Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 17: 359-365, 2005.
51. Esposito E, Genovese T, Caminiti R, Bramanti P, Meli R and Cuzzocrea S: Melatonin reduces stress-activated/mitogen-activated protein kinases in spinal cord injury. J Pineal Res 46: 79-86, 2009.
52. Kawabata H, Setoguchi T, Yone K, et al: High mobility group box 1 is upregulated after spinal cord injury and is associated with neuronal cell apoptosis. Spine 35: 1109-1115, 2010.
53. Huang Y, Xie K, Li J, et al: Beneficial effects of hydrogen gas against spinal cord ischemia-reperfusion injury in rabbits. Brain Res 1378: 125-136, 2010.
54. Wang Q, Ding Q, Zhou Y, et al: Ethyl pyruvate attenuates spinal cord ischemic injury with a wide therapeutic window through inhibiting high-mobility group box 1 release in rabbits. Anesthesiology 110: 1279-1286, 2009.
55. Faraco G, Fossati S, Bianchi ME, et al: High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 103: 590-603, 2007.
56. Crowe MJ, Bresnahan JC, Shuman SL, Masters JN and Beattie MS: Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 3: 73-76, 1997.
57. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ and Anderson DH: The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 99: 11830-11835, 2002.
58. Huang Y, Yin H, Han J, et al: Extracellular HMGB1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 7: 799-808, 2007.
59. Moser B, Szabolcs MJ, Ankersmit HJ, et al: Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am J Transplant 7: 293-302, 2007.
60. Kao YH, Jawan B, Goto S, et al: High-mobility group box 1 protein activates hepatic stellate cells in vitro. Transplant Proc 40: 2704-2705, 2008.
61. Matsuoka N, Itoh T, Watarai H, et al: High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest 120: 735-743, 2010.